The $60m acquisition entitles Zydus to purchase two generic drugs – Micro-K and Potassium Chlroide ER capsule products – from Nesher, reported economictimes.indiatimes.com.
With this acquisition, Zydus will take over all of Nesher’s existing and pipeline ANDAs, certain manufacturing facilities and a full fledged research and development lab.
The agreement further allows Zydus for manufacturing and distributing Nesher’s generic controlled substances in the US market.
Further financial terms of the agreement are been disclosed.
Zydus Cadila chairman and managing director Pankaj Patel said they believe that this new development gives them access to a difficult-to-develop product pipeline, expertise and infrastructure that will add value to their operations in the US.